Clinical trials: Rabies
Rabies Vaccine Allergy, Vaccination Adverse Event
The Post-Marketing Safety and Immunogenicity Research of Speeda® Rabies Vaccine for Human Use
The objective of this study was to achieve the post-marketing safety and immunogenicity research of Speeda® rabies vaccine for human use from Chengda Bio
- Conditions
- Rabies Vaccine Allergy, Vaccination Adverse Event, Anti-D Antibodies
- Trial name
- NCT01821911
- Testing
- Zagreb2-1-1, Essen
- Where
- 3 sites in China
- Volunteers
- 10,500 people, healthy volunteers welcome
- Sponsor
- Beijing Center for Disease Control and Prevention
Rabies
Adherence to Anti-rabies Post-exposure Prophylactic Protocols
This study aims to investigate physicians' adherence to Advisory Committee on Immunization Practices (ACIP) guidelines regarding Anti-rabies post-exposure prophylaxis in Egypt.
- Trial name
- NCT07012083
- Testing
- survey
- Where
- Egypt
- Volunteers
- 214 people
- Sponsor
- Tanta University
Dog Bite
Observation Study an Immunogenicity Modified TRC-ID Regimen With CPRV With or Without Rabies Immunoglobulin in Children
To determine Immunogenicity and Safety Study of Modified TRC-ID Regimen with A New Chromatographically Purified Vero Cell Rabies Vaccine (SPEEDA®) as post exposure rabies intradermal regimen with or without Rabies Immunoglobulin…
- Trial name
- NCT02339896
- Testing
- rabies vaccine
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Queen Saovabha Memorial Institute
Intradermal (ID) Vaccination Device
Intradermal Rabies Immunization Using NanoJect: A Comparative Study
The study is planned as a single-center, randomized, double-blind placebo-controlled, comparative Phase I, first-in-man study to assess the safety and tolerability of the NanoJect™ device, and the immunogenicity of the rabies…
- Trial name
- NCT02538185
- Testing
- NanoJect device (DebioJect™), Classical syringe (1mL Becton Dickinson (BD) Luer-Lock™) with a 25 Guage (G) needle (Terumo® Neolus), Classical syringe (1mL BD Luer-Lock™) with a 22G needle (Terumo® Neolus)
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- University of Lausanne Hospitals
Rabies
Immunogenicity and Safety Study of A New Chromatographically Purified Vero Cell Rabies Vaccine With ID Regimen and ERIG
A comparative,randomized (1:1)study to evaluate the safety and immunogenicity of a new chromatographically purified vero cell rabies vaccine (SPEEDA) and chromatographically purified vero cell rabies vaccine (SPEEDA)which is…
- Trial name
- NCT01137045
- Testing
- SPEEDA and TRCS SPEEDA
- Where
- 2 sites in Thailand
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Queen Saovabha Memorial Institute
Rabies (Healthy Volunteers)
Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adults in Thaïland
Primary Objective: To describe the immune response induced by VRVg-2 and Verorab vaccines at D14 and D35 when co-administered with Human Rabies Immunoglobulins (HRIG) at D0, according to the Zagreb (2-1-1) IM regimen in healthy…
- Trial name
- NCT04594551
- Testing
- Purified vero rabies vaccine - serum free, Purified inactivated rabies vaccine, Human rabies immunoglobulins
- Where
- 3 sites in Thailand
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Rabies Prevention, Rabies Exposure
Study of Intradermal Administration of PCEC Rabies Vaccine
The purpose of this study is to determine immunogenicity and safety of intradermal administration of the PCEC rabies vaccine in adults.
- Trial name
- Rabies-ID (NCT01044199)
- Testing
- PCEC rabies vaccine given intradermally, PCEC rabies vaccine administered intramuscularly
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Rabies Post-exposure Prophylaxis
Purified Rabies Vaccine for Human Use (Chick-embryo Cell)
Evaluate the immunogenicity and safety of rabies vaccine given in a post-exposure prophylaxis regimen to healthy children and adults aged 10-60 years.
- Trial name
- NCT00345319
- Testing
- rabies vaccine
- Where
- China
- Volunteers
- 630 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Vaccine Reaction
A Comparison of Safety and Immunogenicity of Rabies Pre Exposure Prophylaxis Regimen Between Gvt of India Approved and WHO Approved.
The goal of this clinical trial is to compare WHO recommended PrEP Vaccination Schedule, 2 doses 0.2ml 2 sites (0.1ml each site) on day 0 and day 7 and Government of India currently recommended PrEP Schedule, 0.1ml 3 doses on day…
- Trial name
- NCT06066294
- Testing
- Regimen 1, Regimen 2
- Where
- India
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Kempegowda Institute of Medical Sciences, Bangalore
Rabies Prevention
Early Rabies Vaccine Immunization in Primary School Children
700 male and female healthy school-children (age 5 to 8) in Thailand were randomized to receive 2 or 3 primary rabies vaccine doses (PCECV, Rabipur) given intradermally in a dose of 0.1mL into the skin in the deltoid region.
- Trial name
- I49P1 (NCT01107275)
- Testing
- rabies vaccine
- Where
- Thailand
- Volunteers
- 703 people, healthy volunteers welcome
- Sponsor
- Provincial Public Health Office, Phetchabun
Plasmodium Falciparum Malaria
Phase 1 Trial of a Malaria Vaccine in Young Kenyan Children
To assess the safety and reactogenicity of the FMP-1/AS02A malaria vaccine in malaria-exposed children living in western Kenya and aged 12-47 months
- Trial name
- NCT00317473
- Testing
- FMP1/AS02A Malaria vaccine, Imovax Rabies vaccine
- Where
- Kenya
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Rabies
Immunity Persistence After Abridged Intradermal Rabies PEP
After exposure, rabies can be prevented in almost 100% of cases by the administration of sufficient and timely post-exposure prophylaxis (PEP).
- Trial name
- RESIST-3 (NCT04829630)
- Testing
- rabies vaccine
- Where
- 2 sites in Cambodia, Madagascar
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Rabies, Japanese Encephalitis
Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects
Establish non-inferiority of the immune response and evaluate the safety and tolerability of Rabies and Japanese Encephalitis (JE) vaccines given concomitantly or alone and according to either of 2 schedules for preexposure…
- Trial name
- NCT01662440
- Testing
- Rabies, Japanese Encephalitis
- Where
- 3 sites in Austria, Germany and 1 more
- Volunteers
- 661 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Rabies
Human Rabies Immunoglobulin (HRIG)- Dosage Determination and Interference With the Active Immune Response
Dosage of rabies immune globulin was calculated from the victim's body weight, then the amount of rabies immune globulin would be injected as much as possible to all of the wounds.
- Trial name
- NCT01610362
- Testing
- Human Rabies Immune Globulin
- Where
- Thailand
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Queen Saovabha Memorial Institute
Rabies
Immunogenicity and Safety of Different Dosages of Rabies Vaccine (Serum-free Vero Cell)
To describe the immunogenicity and safety of two dosages of Sinovac rabies vaccine, as well as compared the differences with the marked WHO PQ rabies vaccine Verorab® in a post-exposure prophylaxis (PEP) schedule.
- Trial name
- NCT07055880
- Testing
- Rabies Vaccine (Serum-free Vero Cell), Freeze-dried, Verorab®
- Where
- Pakistan
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Rabies Post-exposure Prophylaxis
Study to Evaluate GR1801's Efficacy and Safety
The goal of this clinical trial is to compare the efficacy and safety of GR1801 injection with Human Rabies Immunoglobulin(HRIG) in patients with WHO Category 3 rabies exposure. Patients will receive GR1801 injection or HRIG.
- Trial name
- NCT05846568
- Testing
- GR1801, Human Rabies Immunoglobulin(HRIG), Rabies Vaccine
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Rabies
Immunogenicity and Safety of Verorab™ in Indian Population
To demonstrate that rabies vaccine administered according to the Thai Red Cross, (TRC)-ID regimen (2-2-2-0-1-1) is not inferior to rabies vaccine administered according to the ESSEN IM regimen in terms of Geometric Mean Titers…
- Trial name
- NCT00260351
- Testing
- Purified Verocell Rabies Vaccine
- Where
- 3 sites in India
- Volunteers
- 405 people
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Rabies
Immunogenicity and Safety of Rabies Vaccine, Administered With Two Different Simulated Post Exposure Schedules
This study was planned to establish the non-inferiority of Rabipur administered as simulated post exposure Zagreb schedule as compared to Essen schedule, in healthy Indian adult subjects.
- Trial name
- NCT01365494
- Testing
- Purified Chick Embryo Cell Inactivated Rabies Vaccine
- Where
- 3 sites in India
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Rabies in Animals, Worms; Intestine
Integrating Community Interventions to Eliminate Neglected Tropical Diseases
The overarching goal of this project is the elimination of two neglected tropical diseases (NTD): soil-transmitted helminthiasis and rabies.
- Trial name
- NCT03667079
- Testing
- integrated delivery of deworming and vaccination, Mass deworming only, Mass vaccination of dogs
- Where
- United States
- Volunteers
- 28,143 people, healthy volunteers welcome
- Sponsor
- Washington State University